Extract

This study consists of a 4 week run-in period with a Ca based phosphate binder and 12 weeks treatment period by MCI-196 or placebo, (both on Ca based phosphate binder). During the treatment period, MCI-196 or placebo will be titrated every 3 weeks.

Inclusion criteria

• chronic kidney disease ,dialysis ,Hyperphosphatemia

Country

• Czech Republic
• France
• Germany
• Italy
• Macedonia, the former Yugoslav Republic of
• Poland
• Serbia
• South Africa
• Spain
• United Kingdom

Links

• ictrp
• nct